Bioequivalence of Azacitidine 300 Mg Film-Coated Tablets in Adult Patients with Acute Myeloid Leukaemia (AML)
A Randomized, Single Oral Dose, Open Label, Two Treatment, Crossover study to investigate the bioequivalence of the Test Product Azacitidine 300 mg Film coated tablets relative to Reference Product Onureg® 300 mg Film Coated Tablets in adult patients with AML under fasting conditions
Acute Myeloid Leukaemia
DRUG: Azacitidine|DRUG: Onureg
Cmax, Maximum measured plasma concentration over the time span specified, 5 hours|AUC0-t, The area under the plasma concentration versus time curve, from time (0) to the last measurable concentration (t), as calculated by the linear trapezoidal method., 5 hours
AUC0-∞, The area under the plasma concentration versus time curve from time (0) to infinity., 5 hours|Kel, Apparent first-order elimination or terminal rate constant, 5 hours|Tmax, Time of the maximum measured plasma concentration., 5 hours|T1/2el, The elimination or terminal half-life., 5 hours|Adverse Events (AEs), Adverse Events (AEs), Day 4|Change in clinical safety labs, Descriptive Change in clinical safety labs, Day 4
A Randomized, Single Oral Dose, Open Label, Two Treatment, Crossover study to investigate the bioequivalence of the Test Product Azacitidine 300 mg Film coated tablets relative to Reference Product Onureg® 300 mg Film Coated Tablets in adult patients with AML under fasting conditions